TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02031666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-56021927 capsule
Description: Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
Study: NCT03342196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness.
Study: NCT05801068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor Xa Inhibitor
Description: Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
Study: NCT03242174

Intervention type: OTHER
Intervention: Health Behavior Questionnaire Packet
Description: Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete

Intervention type: OTHER
Intervention: Health Behavior Questionnaire Packet
Description: Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
Study: NCT04668872

Intervention type: RADIATION
Intervention: Y90 TARE
Description: Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
Study: NCT02031666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 tablet
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
Study: NCT01632956

Intervention type: BEHAVIORAL
Intervention: virtual support group
Description: Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
Study: NCT04136990

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated ACL reconstruction
Description: Isolated ACL reconstruction using the bone-patellar tendon autograft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL + LEAT reconstruction
Description: ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
Study: NCT01756599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Study: NCT04668872

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
Study: NCT04322097

Intervention type: DEVICE
Group type: OTHER
Intervention: Lingual Muscle Stimulation
Description: Tongue protrudor muscles will be stimulated
Study: NCT02179359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Toxicity Ablative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Stem Cell Infusion Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Preparative Regimen
Description: * Alemtuzumab~* Cyclophosphamide~* Fludarabine~* Total Body Irradiation (TBI)~* Stem Cell Infusion Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloablative Preparative Regimen
Description: * Alemtuzumab~* Cyclophosphamide~* Busulfan~* Stem Cell Infusion Day 0
Study: NCT03664882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine M016455
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT04912947

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immusystem
Description: Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo capsule
Study: NCT02432898

Intervention type: DEVICE
Intervention: 3D OCT-1
Description: Spectral Domain OCT Device

Intervention type: DEVICE
Intervention: 3D OCT-2000
Description: Spectral Domain OCT Device

Intervention type: DEVICE
Intervention: DRI OCT-1
Description: Swept Source OCT Device

Intervention type: DEVICE
Intervention: NW-300
Description: Fundus Camera

Intervention type: DEVICE
Intervention: CT-1P
Description: Tonometry

Intervention type: DEVICE
Intervention: TRK-2P
Description: Tonometry, Corneal Topography

Intervention type: DEVICE
Intervention: SP-1P
Description: Specular Microscopy

Intervention type: DEVICE
Intervention: SL-D701
Description: Slit Lamp Imaging
Study: NCT04322097

Intervention type: OTHER
Group type: OTHER
Intervention: Mandibular advancement
Description: Outcome variables will be assess with and without mandibular advancement

Intervention type: OTHER
Group type: OTHER
Intervention: Postural maneuvers
Description: Outcome variables will be measured with and without postural maneuvers

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Morphometrics
Description: A digital camera with laser pointers will be used to capture a series of craniofacial photographs (frontal, profile and neck extended) and intra-oral photographs (junction of the hard and soft palate, airway, or base of tongue).

Intervention type: OTHER
Group type: OTHER
Intervention: Tongue Force Exercise
Description: The patient will place a small bulb behind their lower incisors and will press using their tongue as hard as possible for two seconds. This exercise will be repeated four times, with 30 seconds of rest in between each attempt. The patient will then be instructed to press and hold their tongue against the bulb as hard as possible for 35 seconds. This exercise will be repeated three times, with 2 minutes of rest in between each attempt.

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: The patient will undergo an MRI scan of the head and neck.

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography (PSG) - Split Night
Description: The patient will undergo a polysomnography (PSG). The PSG study will include monitoring of EEG, submental EMG, EOG, SpO2, tidal airflow, thoraco-abdominal efforts, and body position. The patient will spend half of the night at baseline (i.e. no intervention), and the second half with lingual muscle stimulation activated.
Study: NCT03617263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg Tablet
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
Study: NCT02432898

Intervention type: DEVICE
Intervention: MC-4S
Description: Visual Acuity Testing
Study: NCT03773471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health App
Description: ArthritisPower App
Study: NCT03976362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to olaparib, tablets
Study: NCT02226601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 3 days perioperative Aprepitant once a day
Study: NCT03617263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Study: NCT03636243

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vascularly biological assessment
Description: 22.5 ml of blood will be collected at day -15, month 3 and month 12.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vascularly biological assessment
Description: 22.5 ml of blood will be collected at day -15, month 3 and month 12.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of vasomotor endothelial function
Description: Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of vasomotor endothelial function
Description: Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.
Study: NCT02226601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 days perioperative Placebot once a day
Study: NCT04472195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation Airway Coaching
Description: Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
Study: NCT03636243

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of arterial compliance
Description: Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of arterial compliance
Description: Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Exploration of microcirculation
Description: The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Exploration of microcirculation
Description: The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Venous Doppler Ultrasound
Description: aneurysm screening at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Venous Doppler Ultrasound
Description: aneurysm screening at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arterial pressure measurement
Description: measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arterial pressure measurement
Description: measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intima-Media Thickness measurement
Description: Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12
Study: NCT03440710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BET
Description: Balloon Eustachian Tuboplasty
Study: NCT03128021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Pill
Description: Double-blinded, randomly assigned

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram Pill
Description: Double-blinded, randomly assigned

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blinded, randomly assigned
Study: NCT03440710

Intervention type: PROCEDURE
Group type: OTHER
Intervention: BET
Description: Balloon Eustachian Tuboplasty
Study: NCT02584114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peak app for memory training
Study: NCT03636243

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intima-Media Thickness measurement
Description: Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Exploration of neuropathy
Description: non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Exploration of neuropathy
Description: non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12
Study: NCT04016207

Intervention type: DRUG
Intervention: Guanfacine
Description: regular treatment
Study: NCT02764970

Intervention type: DRUG
Intervention: Ivabradine 7.5mg orally
Description: additive use to the standard medication with bisoprolol
Study: NCT03170050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YYD701-2
Description: HA Filler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Perlane Lidocaine
Description: HA Filler
Study: NCT01003366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bevel direction during central venous catheterization
Description: approaching the IJV with the needle bevel facing down

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bevel direction during central venous catheterization
Description: approaching the IJV with the needle bevel facing up
Study: NCT02446106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup with MSG
Description: 0.5% MSG + 0.48% salt

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control soup no MSG
Description: Negative control match for sodium (no MSG + 0.635% salt)
Study: NCT04596488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400mg
Description: HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
Study: NCT04047407

Intervention type: DEVICE
Intervention: Suprathreshold pain stimulation
Description: Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized.

Intervention type: DEVICE
Intervention: Suprathreshold pain stimulation
Description: Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized.
Study: NCT01798498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Princess® VOLUME
Study: NCT04112810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: 100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
Study: NCT02851134

Intervention type: GENETIC
Intervention: genetic analysis
Description: genetic (Whole Exome Sequencing )

Intervention type: GENETIC
Intervention: genetic analysis
Description: genetic (Whole Exome Sequencing )

Intervention type: BIOLOGICAL
Intervention: blood and stools samples
Description: biological collection
Study: NCT02584114

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-memory training group
Study: NCT03277105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dara SC
Description: Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Study: NCT03636243

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: level of physical activity
Description: pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: level of physical activity
Description: pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12
Study: NCT03277105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara SC
Description: Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dara IV
Description: Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Study: NCT03636243

Intervention type: OTHER
Group type: OTHER
Intervention: thoracic scanner
Description: non-injected thoracic scanner visit at month 3
Study: NCT02349191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omental transposition for mild Alzheimers disease
Description: An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
Study: NCT03526809

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan and FDG-PET scan
Description: Scanning with MRI and FDG-PET
Study: NCT01857388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentCorps
Study: NCT01671189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Reminder Software Tool
Description: The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
Study: NCT01778881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage and stretching exercises
Description: The routine to be used in this group (stretching, massage, and diaphragmatic breathing).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation and imagination therapies
Description: The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage, exercises, relaxation and imagination therapies
Description: The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
Study: NCT01574157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.